title: [Combination of gentamycin and amikacin with rifampicin, ethambutol and isoniazid on selected standard strains of Mycobacterium species in experiments done in vitro and in vivo].
abstract: The authors present results of in-vivo and in-vitro studies of combined effect of gentamycin , amikacin and rifampicin , ethambutol, isoniazide on selected standard strains of Mycobacterium sp. (Myc. H37Rv, Myc. An5, Myc. wells, Myc. kirchberg, Myc. kansasii, Myc. intracellulare, and Myc. fortuitum). In in-vitro studies the synergistic effect of gentamycin and amikacin with the tuberculostatic drugs was demonstrable on all Mycobacterium strains. The weakest effect was seen on Myc. fortuitum colonies. In-vivo studies have also shown this synergistic effect on all studied strains, and a much weaker effect when used in monotherapy. The authors have shown the possibility of using combination of gentamycin and amikacin with RMP, EMB, INH in treating Myc. intracellulare infections.
authors.forename: M
authors.initials: M
authors.lastname: Janowiec
authors.forename: Z
authors.initials: Z
authors.lastname: Andrzejczyk
authors.forename: J
authors.initials: J
authors.lastname: Marczewska
mesh_terms: D000583:Amikacin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000995:Antitubercular Agents / Q000494:pharmacology*; D004977:Ethambutol / Q000494:pharmacology; D005839:Gentamicins / Q000494:pharmacology; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009161:Mycobacterium / Q000187:drug effects*; D009164:Mycobacterium Infections / Q000188:drug therapy*; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy*; D009170:Nontuberculous Mycobacteria / Q000187:drug effects*; D012293:Rifampin / Q000494:pharmacology; D013045:Species Specificity
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D005839:Gentamicins; D000583:Amikacin; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin
vernacular_title: Skojarzone działanie gentamycyny i amikacyny z ryfampicyna etambutolem i hydrazydem kwasu izonikotynowego na dobrane szczepy wzorcowe z rodzaju Mycobacterium w doświadczeniach in vitro i in vivo.